8-K: Chrome Holding Co. Files Second Amended Bankruptcy Plan

Chrome Holding Co. (formerly 23andMe Holding Co.) has filed its Second Amended Joint Plan of Reorganization and Disclosure Statement in its Chapter 11 bankruptcy proceedings, detailing asset sales and settlement of massive data breach claims.

Summary

• Chrome Holding Co. and its debtor affiliates are undergoing Chapter 11 bankruptcy proceedings, jointly administered under Case No. 25-40976-357, initiated on March 23, 2025.
• The company has sold substantially all of its 'Chrome Debtors' assets for $302.5 million to 23andMe Research Institute (formerly TTAM Research Institute) through the Chrome Sale Transaction, which closed on July 14, 2025.
• The 'Lemonaid Debtors' (telehealth business) are being sold to Bambumeta Ventures, LLC for $10 million, a higher offer than the initial $2.5 million from TTAM.
• The plan addresses significant liabilities, including over $51 trillion in asserted claims from approximately 258,000 proofs of claim, with governmental units asserting over $6 billion.
• Settlement agreements have been reached for data breach claims: U.S. Data Breach Class Settlement (minimum $30 million, capped at $50 million), Canadian Data Breach Class Settlement ($3.25 million), and Pixel Class Settlement ($3.25 million).
• The Bankruptcy Court has preliminarily approved these class settlements and orally approved the assumption of the U.S. Data Breach Arbitration Settlement Agreement.
• A Plan Administration Trust will be established to wind down the Debtors' affairs, reconcile claims, and distribute proceeds to stakeholders.
• The Chrome Debtors anticipate approximately $222 million in cash for distribution to Allowed Claims and Interests, contingent on reducing the massive claims pool, including disallowing ~160,000 potentially fraudulent claims totaling ~$876 million.
• The company secured a debtor-in-possession (DIP) financing facility of up to $35 million, later increased to $60 million, which has since been repaid in full.

Sentiment

Score: 3

Explanation: The company is in Chapter 11 bankruptcy, facing immense liabilities from data breaches and operational challenges. While asset sales and settlement agreements provide a path to resolution, the scale of claims and ongoing litigation indicate a highly distressed situation with significant uncertainty for equity holders.

Positives

• Successful sale of substantially all Chrome Debtors' assets for $302.5 million, providing significant proceeds for creditor distributions.
• Secured a higher offer of $10 million for the Lemonaid telehealth business, exceeding the initial $2.5 million bid.
• Settlement agreements reached for major data breach class actions (U.S., Canadian, Pixel), providing a structured path to resolve substantial liabilities.
• Bankruptcy Court has preliminarily approved key settlement agreements and the assumption of the U.S. Data Breach Arbitration Settlement Agreement, indicating progress towards plan confirmation.
• The company successfully obtained and repaid a $60 million DIP financing facility, ensuring liquidity during the Chapter 11 process.
• An independent investigation into potential claims against company insiders was conducted, and the Chrome Purchase Agreement was amended to preserve these causes of action for the estate.

Negatives

• The company has not recognized any net profits since its inception, despite generating over $200 million in annual revenues prior to bankruptcy.
• Macroeconomic headwinds, rising inflation, declining consumer interest in genetic testing, and increased competition severely impacted the company's liquidity and revenue.
• The 2023 Cyber Security Incident compromised personal information of approximately seven million customers, leading to extensive litigation and regulatory investigations.
• Total asserted claims against the Debtors exceed $51 trillion from ~258,000 proofs of claim, including over $6 billion from governmental units, posing a significant challenge to full recovery for all stakeholders.
• Approximately 160,000 potentially fraudulent claims totaling ~$876 million have been identified, requiring extensive objection and reconciliation efforts.
• The State of California has publicly stated its intent to assert administrative claims exceeding $1 billion, which could materially erode distributable value.
• Appeals of the Chrome Sale Order by California and CAVEAT remain pending, introducing uncertainty and potential delays.

Risks

• Uncertainty regarding the length of Chapter 11 cases and potential adverse effects on distributable value.
• Risk of non-confirmation of the plan by the Bankruptcy Court, potentially requiring modifications or leading to alternative, less favorable plans.
• Possibility that releases, injunctions, and exculpation provisions in the plan may not be approved, potentially leading to withdrawal of support from certain parties.
• Risk of non-occurrence of the Effective Date if conditions precedent are not met or waived, leading to the plan being null and void.
• Potential conversion of Chapter 11 cases to Chapter 7 liquidation, which could result in significantly lower recoveries for creditors and equity holders.
• Risk that one or more Chapter 11 cases may be dismissed, preventing plan confirmation for applicable debtors and leading to lower recoveries.
• Uncertainty in consummating the Lemonaid Sale Transaction due to potential failure to obtain governmental approvals or better offers.
• Parties in interest may object to the classification of claims and interests, potentially delaying or altering the plan.
• The plan relies on estimates and assumptions that may prove incorrect, leading to actual financial conditions and results differing materially from expectations.
• Potential for additional litigation, including appeals of the Sale Order, which could be expensive and time-consuming, affecting financial performance and plan implementation.
• Uncertainty in the timing and amount of distributions due to the massive claims pool and ongoing claims administration process.
• Inability to guarantee the preservation of over $1 billion in U.S. federal Net Operating Losses (NOLs), which could be materially reduced or lost.
• Changes in interest rates may affect the fair market value of distributions.
• Risks associated with foreign bankruptcy, insolvency, or creditor protection proceedings, and potential non-recognition of the plan in foreign jurisdictions.
• The telehealth market is highly competitive, volatile, and subject to extensive governmental regulation, posing risks to the remaining Lemonaid business.
• Reliance on contractual relationships with Professional Medical Corporations (PMCs) and third-party suppliers for the telehealth business, with risks of non-continuation or regulatory non-compliance.
• Ongoing liquidity restraints and uncertainty regarding the adequacy of cash on hand to satisfy Chapter 11 case obligations.
• Settlement agreements may not receive final approval or could terminate if a high threshold of claimants opt out, affecting distributions and plan confirmation.

Future Outlook

The plan's primary objective is to maximize value for all stakeholders and distribute available property in accordance with bankruptcy priorities, aiming to avoid the delays and costs of Chapter 7 liquidation. The Chrome Debtors may pursue an Equity Sale Transaction to reorganize and preserve equity interests, rather than liquidate. The company expects to pay all creditors in full and potentially provide meaningful distributions to equity holders, contingent on successful claims reconciliation and final approvals of settlement agreements.

Management Comments

• The Special Committee of the Board of Directors and the boards of directors, managers, or members of each Debtor subsidiary have approved the transactions contemplated by the Plan and recommend that all voting parties accept the Plan.
• The Debtors believe that the Plan accomplishes the objective of maximizing value for all stakeholders and is in the best interest of the Estates.
• The Debtors believe that Confirmation of the Plan will avoid the lengthy delay and significant incremental costs of liquidation under chapter 7 of the Bankruptcy Code.
• The Debtors believe the releases, exculpation, and injunction are an integral component of the Plan, which is expected to pay all creditors in full and may provide meaningful distributions to holders of the Company's equity interests.
• The Debtors intend to enforce their rights under the U.S. Data Breach Arbitration Settlement Agreement and Holders of U.S. Data Breach Arbitration Represented Claims will receive distributions in accordance with its terms.

Industry Context

The company, a pioneer in direct-to-consumer genetic testing and telehealth, has been significantly impacted by adverse market conditions, including rising inflation, declining consumer spending on genetic testing, and increased competition in both genetic ancestry testing and telehealth. The telehealth market itself is described as relatively new and unproven, with fierce competition from traditional healthcare providers and new direct-to-consumer entrants. Regulatory risks, particularly concerning governmental regulation of prescribing controlled substances and compliance with extensive healthcare regulations, are also noted.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are detailed in the filing for direct comparison to industry standards. The filing primarily focuses on the company's internal financial and legal challenges within the context of its bankruptcy proceedings.

Management Changes

Corporate Governance

Legal Proceedings

• Over 40 putative class action lawsuits centralized into the multi-district Cyber Class Action following the October 2023 Cyber Security Incident.
• Approximately 35,000 U.S. arbitration claims asserted or threatened against the company due to the Cyber Security Incident.
• Three class actions filed in Canadian courts and a pre-arbitration demand from a U.K. firm (3,720 customers) related to the Cyber Security Incident.
• Regulatory investigations by the Federal Trade Commission (FTC), Multi-State Attorneys General, and 12 foreign regulators (including a joint Canada/U.K. investigation) concerning the Cyber Security Incident.
• A putative class action lawsuit, A.J., et al. v. Lemonaid Health Inc., alleging damages from website operations (Pixel Class Action).
• Prepetition settlement agreements executed with certain Cyber Security Incident claimants.
• U.S. Data Breach Class Settlement Agreement (minimum $30 million, capped at $50 million) and Canadian Data Breach Class Settlement Agreement ($3.25 million) reached and preliminarily approved by the Bankruptcy Court.
• Pixel Settlement Agreement ($3.25 million) reached and preliminarily approved by the Bankruptcy Court.
• U.S. Data Breach Arbitration Settlement Agreement assumed by the Debtors, with oral approval from the Bankruptcy Court.
• Adversary proceedings initiated by certain states in June 2025, seeking determination of consumer property interests in genetic data.
• Objections to the Chrome Sale Transaction by state Attorneys General and Global BioData Trust (CAVEAT), which were overruled by the Bankruptcy Court.
• Appeals of the Sale Order by California and CAVEAT to the U.S. District Court and the Eighth Circuit Court of Appeals remain pending, though stays were denied.
• Emergency motion filed by Debtors to object to approximately 160,000 potentially fraudulent claims totaling ~$876 million, which was granted by the Bankruptcy Court.
• U.S. Trustee filed an objection to certain release provisions in the Plan, which is expected to be litigated at the Confirmation Hearing.

Related Party Transactions

• Ms. Anne Wojcicki, co-founder and former CEO, submitted non-binding indications of interest to acquire the company's outstanding equity, including a $0.40/share offer (July 29, 2024) and a $2.53/share offer with New Mountain Capital (February 20, 2025), both rejected by the Special Committee.
• Ms. Wojcicki's March 6, 2025, proposal included $0.41/share cash and contingent value rights, and a March 10, 2025, update offered $20 million in additional capital, both rejected.
• Ms. Wojcicki converted 4,931,692 shares of Class B Common Stock into Class A Common Stock on June 9, 2025, decreasing her aggregate voting power.

Stakeholder Impact

• Shareholders (HoldCo Interests) will receive a pro rata portion of Class B Plan Administration Trust Interests, which are residual and subject to significant uncertainty, with treatment still under negotiation.
• Creditors (various classes) are projected to receive distributions from the Plan Administration Trust, with some settlement classes (U.S. Data Breach, Canadian Data Breach, Pixel) estimated at 100% recovery, but overall recovery is contingent on successful claims reconciliation.
• Customers impacted by the Cyber Security Incident are subject to various settlement agreements, offering benefits or distributions from settlement funds.
• Employees faced a significant headcount reduction (40% or ~200 employees) in November 2024 as part of cost-cutting measures.
• Governmental Units have asserted over $6 billion in claims, and the State of California may assert an additional $1 billion administrative claim, impacting the overall distributable value for other stakeholders.

Next Steps

• Voting on the Second Amended Joint Plan by November 6, 2025.
• Confirmation Hearing on the Plan scheduled for November 19, 2025.
• Debtors-appellees to file appeal brief in District Court by October 6, 2025.
• CAVEAT to file appeal brief in Court of Appeals by October 8, 2025.
• California and CAVEAT to file reply in District Court by October 20, 2025.
• Final approval of U.S. Data Breach Class Settlement, Canadian Data Breach Class Settlement, and Pixel Settlement Agreement after Plan Confirmation.
• Ongoing claims reconciliation process, including objections to potentially fraudulent claims and governmental unit claims.
• Appointment of a Plan Administrator and Representatives to oversee the Plan Administration Trust and wind down operations.
• Potential pursuit of an Equity Sale Transaction for Chrome Debtors to reorganize instead of liquidate.

Key Dates

Recommendation

The company is in Chapter 11 bankruptcy, indicating severe financial distress and a high likelihood of significant dilution or complete loss for existing equity holders. While asset sales are underway, the massive volume of asserted claims (over $51 trillion) and ongoing legal challenges create extreme uncertainty regarding any residual value for shareholders. The stock has already been delisted from NASDAQ and trades on the OTC market, reflecting its distressed status. The plan's objective is to maximize value for *all stakeholders*, which in a liquidation scenario typically prioritizes creditors over equity. The 'TBD' recovery for HoldCo Interests further underscores the speculative nature and high risk of holding this stock.

Keywords

Chapter 11, Bankruptcy, Reorganization Plan, SEC Filing, Data Breach Settlement, Asset Sale, Telehealth, Genetic Testing, Claims Reconciliation, Liquidation, Corporate Governance, Risk Factors, Creditor Claims, Legal Proceedings, DIP Financing